New Frontiers in the Management of Hormone-Refractory Prostate Cancer

Program Director: E. David Crawford, MD

Faculty:

Nicholas J. Vogelzang, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Summarize potential efficacy and safety of recent therapeutic approaches for managing hormone-refractory prostate cancer
• Describe the role of novel targeted therapies in the overall treatment of advanced prostate cancer
• Review the latest data on the use of immunotherapy in hormone-refractory prostate cancer

Topics covered include:

• Introduction
• Docetaxel Combinations for the Treatment of HRPC
• Epothilones for the Treatment of HRPC
• Platinum-Based Drugs for the Treatment of HRPC
• Vitamin D–Based Therapy
• Targeted Agents for HRPC
• Atrasentan—An Endothelin Receptor Antagonist
• Active Immunotherapy in the HRPC Setting
• Other Immune Therapy Approaches
• Monoclonal Antibodies
• Drugs That Target Apoptosis
• Inhibitors of Growth Factor Receptor Signaling
• Anthracycline Analogues for HRPC
• Summary—Implications for Clinical Practice